PDF herunterladen
Exp Clin Endocrinol Diabetes 2010; 118(6): 356-359
DOI: 10.1055/s-0029-1243603
Mini Review

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Insulin Signal Transduction in Normal Cells and its Role in Carcinogenesis

K. Müssig1 , H.-U. Häring1
  • 1Division of Endocrinology, Diabetology, Angiology, Nephrology, and Clinical Chemistry, Department of Internal Medicine, University Hospital of Tübingen, Tübingen, Germany
Weitere Informationen

Publikationsverlauf

received 17.11.2009 first decision 17.11.2009

accepted 20.11.2009

Publikationsdatum:
05. Februar 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Convincing epidemiological evidence exists for a causal relationship between increased risk of cancer development and progression and type 2 diabetes mellitus as well as obesity. Though the underlying mechanisms remain elusive, in light of the well-described mitogenic actions of insulin, hyperinsulinaemia in the presence of insulin resistance is probably a key factor. In this short review, an overview over the insulin signalling cascade is given paying special attention to the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI 3-K)/mammalian target of rapamycin (mTOR) pathways which are involved in protein synthesis and cell growth.

Key words

mammalian target of rapamycin - MAPK - mitogen-activated protein kinase - mTOR - phosphatidylinositol 3-kinase - PI 3-K - RafRas - small molecule inhibitors - tumorigenesis

References

  • 1 Adjei AA, Cohen RB, Franklin W. et al . Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.  J Clin Oncol. 2008;  26 2139-2146
    Google Scholar
  • 2 Alessi DR, James SR, Downes CP. et al . Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.  Curr Biol. 1997;  7 261-269
    Google Scholar
  • 3 Baltensperger K, Kozma LM, Cherniack AD. et al . Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes.  Science. 1993;  260 1950-1952
    Google Scholar
  • 4 Burgering BM. A brief introduction to FOXOlogy.  Oncogene. 2008;  27 2258-2262
    Google Scholar
  • 5 Calle EE, Rodriguez C, Walker-Thurmond K. et al . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.  S. adults. N Engl J Med. 2003;  348 1625-1638
    Google Scholar
  • 6 Cheatham B, Kahn CR. Insulin action and the insulin signaling network.  Endocr Rev. 1995;  16 117-142
    Google Scholar
  • 7 Coughlin SS, Calle EE, Teras LR. et al . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.  Am J Epidemiol. 2004;  159 1160-1167
    Google Scholar
  • 8 Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis.  Lancet. 2008;  372 657-668
    Google Scholar
  • 9 Cusi K, Maezono K, Osman A. et al . Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.  J Clin Invest. 2000;  105 311-320
    Google Scholar
  • 10 Davies H, Bignell GR, Cox C. et al . Mutations of the BRAF gene in human cancer.  Nature. 2002;  417 949-954
    Google Scholar
  • 11 Draznin B. Mitogenic action of insulin: friend, foe or ‘frenemy’?.  Diabetologia. 2009; 
    Google Scholar
  • 12 Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).  Biochem J. 2008;  416 375-385
    Google Scholar
  • 13 Han SW, Kim TY, Jeon YK. et al . Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.  Clin Cancer Res. 2006;  12 2538-2544
    Google Scholar
  • 14 Hersey P, Bastholt L, Chiarion-Sileni V. et al . Small molecules and targeted therapies in distant metastatic disease.  Ann Oncol. 2009;  20 ((Suppl 6)) vi35-vi40
    Google Scholar
  • 15 Hess G, Herbrecht R, Romaguera J. et al . Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.  J Clin Oncol. 2009;  27 3822-3829
    Google Scholar
  • 16 Hong DS, Sebti SM, Newman RA. et al . Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies.  Clin Cancer Res. 2009; 
    Google Scholar
  • 17 Hooper, C. Insulin signaling pathways. htpp://www.abcam.com/index.html?pageconfig=resource&idref=10602&pid=7 abcam Inc., Cambridge, MA, USA 23-5-2009
    Google Scholar
  • 18 Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.  Biochem J. 2008;  412 179-190
    Google Scholar
  • 19 Hudes G, Carducci M, Tomczak P. et al . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.  N Engl J Med. 2007;  356 2271-2281
    Google Scholar
  • 20 Jonasch E, Corn P, Pagliaro LC. et al . Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.  Cancer. 2009; 
    Google Scholar
  • 21 Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95 000-dalton subunit of its own receptor.  Science. 1982;  215 185-187
    Google Scholar
  • 22 Kim J, Reber HA, Dry SM. et al . Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.  Gut. 2006;  55 1598-1605
    Google Scholar
  • 23 Lancet JE, Gojo I, Gotlib J. et al . A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.  Blood. 2007;  109 1387-1394
    Google Scholar
  • 24 Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy.  Cancer Lett. 2009;  283 125-134
    Google Scholar
  • 25 Myers Jr MG, White MF. The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains.  Diabetes. 1993;  42 643-650
    Google Scholar
  • 26 Neubauer A, Maharry K, Mrozek K. et al . Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.  J Clin Oncol. 2008;  26 4603-4609
    Google Scholar
  • 27 Pao W, Wang TY, Riely GJ. et al . KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.  PLoS Med. 2005;  2 e17
    Google Scholar
  • 28 Pilarski R. Cowden syndrome: a critical review of the clinical literature.  J Genet Couns. 2009;  18 13-27
    Google Scholar
  • 29 Rinehart J, Adjei AA, Lorusso PM. et al . Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.  J Clin Oncol. 2004;  22 4456-4462
    Google Scholar
  • 30 Rushworth LK, Hindley AD, O'Neill E. et al . Regulation and role of Raf-1/B-Raf heterodimerization.  Mol Cell Biol. 2006;  26 2262-2272
    Google Scholar
  • 31 Sarbassov DD, Guertin DA, Ali SM. et al . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.  Science. 2005;  307 1098-1101
    Google Scholar
  • 32 Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth.  Nature. 2006;  441 424-430
    Google Scholar
  • 33 Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling.  Biochem J. 1998;  333 471-490
    Google Scholar
  • 34 Skolnik EY, Batzer A, Li N. et al . The function of GRB2 in linking the insulin receptor to Ras signaling pathways.  Science. 1993;  260 1953-1955
    Google Scholar
  • 35 Stephens L, Anderson K, Stokoe D. et al . Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B.  Science. 1998;  279 710-714
    Google Scholar
  • 36 Tsai J, Lee JT, Wang W. et al . Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.  Proc Natl Acad Sci USA. 2008;  105 3041-3046
    Google Scholar
  • 37 Ullrich A, Bell JR, Chen EY. et al . Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.  Nature. 1985;  313 756-761
    Google Scholar
  • 38 Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.  J Clin Invest. 1999;  103 931-943
    Google Scholar
  • 39 Vitale A, Volk ML, Pastorelli D. et al . Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety.  Hepatology. 2009; 
    Google Scholar
  • 40 Wang X, Jiang X. Post-translational regulation of PTEN.  Oncogene. 2008;  27 5454-5463
    Google Scholar
  • 41 Watson RT, Shigematsu S, Chiang SH. et al . Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation.  J Cell Biol. 2001;  154 829-840
    Google Scholar
  • 42 Zhang J, Gao Z, Yin J. et al . S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2.  J Biol Chem. 2008;  283 35375-35382
    Google Scholar
  • 43 Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status.  Curr Opin Investig Drugs. 2003;  4 1428-1435
    Google Scholar

Correspondence

Prof. Dr. med. H.-U. Häring

Medizinische Klinik IV

Universitätsklinikum

Tübingen

Otfried-Müller-Str 10

D-72076 Tübingen

Germany

Telefon: +49/7071/2982735

Fax: +49/7071/292784

eMail: hans-ulrich.haering@med.uni-tuebingen.de

      >